Advertisement


Peter G. Shields, MD, on New NCCN Guidelines: Smoking Cessation for Patients With Cancer

2015 NCCN Annual Conference

Advertisement

Peter G. Shields, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the new NCCN Guidelines for helping patients with cancer to stop smoking. Counseling is a critical part of these new recommendations.



Related Videos

Lung Cancer

Gregory A. Otterson, MD, on Adjuvant Therapy and Immunotherapy for Lung Cancer

Gregory A. Otterson, MD, of The Ohio State University Comprehensive Cancer Center and the James Cancer Hospital and Solove Research Institute, discusses the evolution of lung cancer treatment from adjuvant chemotherapy to immunotherapy and the clinical trials underway.

Bladder Cancer

Peter E. Clark, MD, on a Guideline Update in the Management of Bladder Cancer

Peter E. Clark, MD, of the Vanderbilt-Ingram Cancer Center discusses the highlights of the 2015 NCCN Guidelines for bladder cancer in both non–muscle invasive and muscle-invasive disease.

Lung Cancer

Leora Horn, MD, MSc, on Targeted and Emerging Therapies for Metastatic NSCLC

Leora Horn, MD, MSc, of the Vanderbilt-Ingram Cancer Center, discusses the range of treatment options for people with lung cancer, including third generation inhibitors, and the key clinical trials studying alternatives for patients with acquired resistance.

Survivorship

Rebecca H. Johnson, MD, on Fertility Preservation and Cancer

Although guidelines worldwide mandate fertility preservation for newly diagnosed patients within their reproductive window, most patients are still not referred or offered this option. Rebecca H. Johnson, MD, of Mary Bridge Children’s Hospital, explains the steps that need to be taken when counseling patients.

Skin Cancer
Symptom Management

Mario E. Lacouture, MD, on Management of Dermatologic Toxicities Associated With Targeted Therapies

Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.

Advertisement

Advertisement



Advertisement